Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
Date:10/21/2008

hance our customer centric activities. Research

Essentials and Research Specialties again achieved sales growth

exceeding long-term growth targets, and Research Biotech remained

on target to improve its growth rate. Third quarter gains for

three of the four focus areas in SAFC were in-line with first half

2008 performance, with a decline in SAFC's Pharma business

reflecting the impact of adverse economic conditions on

pharmaceutical spending;

-- Increasing reported and adjusted sales in CAPLA (Canada, Asia

Pacific and Latin America) markets by 8.8% and 6.8%, respectively,

in Q3 2008, with a Q3 2008 revenue contribution from these markets

at 20% of sales, consistent with the level achieved for all of

2007. Reported quarterly sales in our focus markets of India and

Brazil increased by 1% and 42%, respectively, with organic growth,

exclusive of currency impacts, of 10% and 23%, respectively. Sales

in China that had increased by 21% and 45% in the first and second

quarters of 2008, respectively, were impacted by government-imposed

operating restrictions related to the Olympic games in that

country, reducing third quarter 2008 sales by 9%, but with full

expectations for a recovery in the final quarter of 2008;

-- Increasing web-based sales through our award winning website by

17.6%. Web-based sales improved to 43% of worldwide Q3 2008

Research-based sales as e-commerce sales to international (Europe

and CAPLA) customers increased by 24.4%. E-commerce sales to U.S.

Research customers were 51% of total U.S. Research sales,

consistent with prior year-to-date levels;

-- Continuing our commitment to achieve $15 million in annual, pretax


'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
2. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
3. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
4. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
5. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
6. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
7. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
10. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
11. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... - Revised Code Demonstrates Strong Commitment to Ethical Information ... ... Pharmaceutical Companies -, ROCKLAND, Mass., July 10 ... will fully implement, the revised,and strengthened PhRMA Code on Interactions ...
... TRENTON, N.J., July 10 Archi-Tech Systems, ... reporting solutions,today announced DART(TM) PromoTrack, a new ... pharmaceutical marketing campaigns and,prescriber promotions. Archi-Tech has ... specific needs of pharmaceutical marketers, seamlessly,integrating disparate ...
... Mixed-Pedigree Pups Can Now Bark Up Family Tree with DNA Testing ... ... tree has never been easier with new cutting-edge DNA testing for mixed-pedigree ... specialty retailer., , , , ,Beginning Tuesday, July 15, PETCO customers will ...
Cached Biology Technology:EMD Serono to Adopt Revised and Strengthened PhRMA Code 2EMD Serono to Adopt Revised and Strengthened PhRMA Code 3EMD Serono to Adopt Revised and Strengthened PhRMA Code 4Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 2PETCO Adds Canine Heritage Breed Test to its Innovative Assortment 2PETCO Adds Canine Heritage Breed Test to its Innovative Assortment 3PETCO Adds Canine Heritage Breed Test to its Innovative Assortment 4
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... and management have not affected all socioeconomic groups equally, as ... awareness and outcomes. This year, the American Association ... Science of Cancer Health Disparities in Racial/Ethnic Minorities and the ... Fla. Findings presented at this year,s meeting will ...
... 2010) -- A new optical imaging technique described in ... is published by the American Institute of Physics, holds ... performed to treat patients with a partially or completely ... heart. Angioplasty involves threading a slender, balloon-tipped ...
... These days people usually don,t die from a heart attack. ... patients eventually succumb to congestive heart failure, the most common ... now offer hope for achieving what the body can,t do: ... Washington have built a scaffold that supports the growth and ...
Cached Biology News:Optical imaging technique for angioplasty 2A strategy to fix a broken heart 2A strategy to fix a broken heart 3
... a genome-wide microRNA (miRNA) expression profiling service ... which enable highly sensitive and specific direct ... arrays for mature miRNA of all species ... Sanger miRBase database (Release 8.2). Our service ...
... Microarrays designed for immunological studies, ... on the flexible and powerful Paraflo ... are available as part of our ... Custom Probe Content Probe ...
... Custom peptide microarrays designed for ... serum samples and built on the ... platform. Thousands of customer specified sequences ... Sciences can provide assistance with custom ...
... for the first time, you can identify ... more efficiently without interferences. The Agilent Multiple ... unwanted, multiple high-abundant proteins from human serum, ... just one device. With this revolutionary system, ...
Biology Products: